Encompass Health Corporation (EHC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, including increased free cash flow and reduced labor costs. The company is expanding capacity and sees significant growth potential in inpatient rehabilitation services. Positive trends in managed care volume and strategic initiatives like the Palantir partnership further bolster sentiment. Despite some uncertainties in Medicare Advantage dynamics, the overall outlook remains optimistic, with solid guidance and strategic expansions. The Q&A section reinforces confidence with detailed responses and plans to address challenges. Consequently, a positive stock price movement is expected over the next two weeks.
Key Financial Performance
2025 Revenue Increased 10.5%, driven by 6% discharge growth and pricing growth benefiting from patient mix and patient outcome quality.
2025 EBITDA Grew 14.9% due to operating leverage and disciplined expense management. Premium labor spend declined by more than $21 million from 2024, even as capacity and patient numbers increased.
Q4 Revenue Increased 9.9% to $1.5 billion, driven by 5.3% discharge growth and a 4.1% increase in net revenue per discharge. Net revenue per discharge benefited from a $2.7 million settlement with a managed care payer related to prior year claims.
Q4 Adjusted EBITDA Increased 15.9% to $335.6 million, supported by reduced premium labor costs and faster Medicare certifications for new hospitals.
2025 Free Cash Flow Increased 18.5% to $818 million, driven by strong cash flow generation, funding capital expenditures, share repurchases, and dividends while maintaining flat long-term debt.
Premium Labor Costs (Q4) Declined $5.8 million from Q4 2024 to $23.8 million, the lowest since Q1 2021. Contract labor FTEs as a percent of total FTEs was 1.1%, also the lowest since Q1 2021.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ERP System Conversion: In October, the company converted its enterprise resource planning system to Oracle Fusion, providing a flexible and sustainable cloud-based IT infrastructure to support business growth.
Strategic Relationship with Palantir: The company extended and expanded its agreement with Palantir, focusing on streamlining admission documentation and enhancing responses to claims denials.
Capacity Expansion: In 2025, the company added 517 beds, including 390 via 8 new hospitals and 127 through additions to existing hospitals. Plans to introduce small-format hospitals in 2027 to facilitate a hub-and-spoke strategy in larger markets.
Revenue and EBITDA Growth: 2025 revenue increased by 10.5%, driven by 6% discharge growth and pricing improvements. EBITDA grew by 14.9% due to operating leverage and disciplined expense management.
Labor Cost Management: Premium labor spend declined by over $21 million from 2024, with contract labor FTEs at their lowest since Q1 2021.
Free Cash Flow: 2025 adjusted free cash flow increased by 18.5% to $818 million, enabling significant investments in operations, share repurchases, and dividends.
Regulatory Preparedness: Prepared for regulatory changes like RCD expansion and TEAM model implementation, leveraging experience and ensuring compliance to minimize risks.
Hub-and-Spoke Strategy: Plans to implement a hub-and-spoke strategy with small-format hospitals starting in 2027 to address growing demand and demographic trends.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Developments: Market anxiety regarding IRF industry regulatory changes, including the extension of RCD and the initiation of the TEAM model, could impact reimbursement criteria and patient flows. Although the company has prepared extensively, these changes pose potential risks to operations and financials.
Reimbursement Criteria: The expansion of RCD into Texas and California introduces risks related to the consistent application of reimbursement criteria by different MACs, which could affect revenue and claims affirmation rates.
TEAM Model Implementation: The TEAM model, an episodic payment pilot, could impact patient flows and financial outcomes in the 89 hospitals in initial markets, despite no downside risk in 2026 under the default track.
Labor Costs: Although premium labor costs have declined, labor cost management remains a challenge, especially in maintaining low contract labor FTEs and managing benefit expenses.
Economic Uncertainties: Economic uncertainties could impact the company's financial performance, particularly in maintaining revenue growth and managing bad debt expenses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Net Operating Revenue: Guidance includes net operating revenue of $6.365 billion to $6.465 billion.
2026 Adjusted EBITDA: Guidance includes adjusted EBITDA of $1.34 billion to $1.38 billion.
2026 Adjusted Earnings Per Share: Guidance includes adjusted earnings per share of $5.81 to $6.10.
Capacity Expansion Plans: The company plans to continue investing in capacity additions, including the introduction of small-format hospitals beginning in 2027 to facilitate a hub and spoke strategy in larger and growing markets.
Regulatory Preparedness: The company is prepared for the expansion of Review Choice Demonstration (RCD) into Texas and California in 2026 and has extensively prepared for the TEAM model implementation, which began on January 1, 2026.
Strategic Relationship with Palantir: The company has extended and expanded its agreement with Palantir, focusing on initiatives to streamline admission documentation and enhance responses to claims denials, with expected benefits in 2026 and beyond.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash Dividends: In 2025, the company returned in excess of $70 million in cash dividends.
Share Repurchases: In 2025, the company allocated $158 million to share repurchases.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the volume trends for 2026, particularly regarding comp issues and the impact of de novos?
A:Douglas Coltharp explained that in the back half of the year, they faced challenging comps, with Q3 '24 total discharges up 8.8% and Q4 up 8.3%. New hospitals skewed towards the back end of the year, with one opening in Q3 and three in Q4. Unit consolidations and closures, such as in Sewickley, PA, and Cincinnati, OH, also impacted volumes, with a headwind of 30 basis points in Q3 and 45 basis points in Q4.
Q:What caused the higher Medicare fee-for-service mix in Q4, and how did other payer classes perform?
A:Douglas Coltharp noted strong fee-for-service growth in Q4, which is their best payer. Challenges arose with one national Medicare Advantage payer, where conversion rates dropped significantly despite high single-digit referral growth. They plan to address this with CMS and implement strategies like AI tools and appeal processes for denials.
Q:What is the impact of the VA program on managed care volume?
A:Patrick Tuer highlighted that the VA program now represents 19% of managed care volume, with discharge growth over 20% for three consecutive quarters, finishing the year with 22% growth. They see significant upside in this segment.
Q:What are the expectations for the team pilot program and its potential impact?
A:Mark Tarr and Patrick Tuer explained that past pilots like BPCI and CJR did not expand after five years, and they grew significantly during those periods. They are not hearing major changes in patient handling from hospitals in impacted markets and see opportunities to backfill volume with other diagnostic categories. They also noted that dialysis patients are exempt from team, and they have capacity to double that volume.
Q:What drove the better-than-expected labor costs in Q4?
A:Mark Tarr and Patrick Tuer attributed it to softening labor markets, reduced turnover, and disciplined premium pay management. They added 300 net RNs in 2025 and achieved efficiencies without sacrificing quality. Douglas Coltharp provided specifics: total SWB per FTE was up 2.1%, core SW up 2.8%, benefits up 2.9%, and premium labor down $5.8 million year-over-year.
Q:What is the status of the Alabama RCD experience and its implications?
A:Douglas Coltharp stated that the affirmation rate is 93%, with most non-affirmed claims being appealed successfully. They expect the rate to improve and believe the go-forward bad debt expense rate will remain consistent with historical levels. Patrick Tuer added that there has been no volume impact in Alabama, and they are expanding capacity in the state.
Q:What is the rationale behind the new small-format hospitals?
A:Douglas Coltharp explained that these 24-bed hospitals address capacity constraints in existing markets and growing neighborhoods. They leverage prefabricated construction and existing management resources, offering favorable returns. Mark Tarr and Patrick Tuer emphasized market density benefits, staff growth opportunities, and scalability.
Q:What is the outlook for Medicare Advantage rates and payer dynamics?
A:Mark Tarr emphasized leading with outcomes and data to demonstrate their value proposition. Douglas Coltharp noted that the growth rate of new MA beneficiaries has declined, and some plans are exiting geographies, shifting patients to fee-for-service, which benefits them.
Q:What are the plans for expanding the use of technology, including the Palantir partnership?
A:Douglas Coltharp mentioned focusing on CRM market analysis, revenue cycle management, and clinical staffing. Patrick Tuer added that they aim to enhance clinicians' roles by reducing documentation burdens, allowing them to focus on patient care.
Q:What is the exposure to provider taxes and supplemental payments?
A:Douglas Coltharp stated that the EBITDA impact from net provider taxes was $21 million in 2025, up from $15.5 million in 2024. They expect this to remain relatively flat in 2026.
Q:Review of Unclear Management Responses
A:Management avoided directly naming the national Medicare Advantage payer with conversion rate issues and did not provide specific details on the percentage of claims won at different appeal levels for the Alabama RCD experience. Additionally, they did not quantify the exact impact of the team pilot program on EBITDA or provide detailed ROI metrics for the Palantir partnership.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alabama expansion
BPCI version
CJR BPCI
CMS application
Encompass Health
Encompass hospital
Fusion cloud
Fusion disruption
Health opportunity
IRF industry
Instructions reminder
Medicare claim
Mr Encompass
Noridian MAC
Officer statement
Palmetto CMS
Pennsylvania provider
Planning Encompass
RCD Pennsylvania
RCD Texas
RCD engagement
RCD initiation
RCD state
Texas California
Texas expertise
addition bed
addition demand
addition investment
addition modality
admission documentation
affirmation claim
affirmation rate
capacity addition
track
EHC Transcript
Encompass Health Corporation (EHC) Q4 2025 Earnings Call Transcript
Positive2-6
The earnings call highlights strong financial performance, including increased free cash flow and reduced labor costs. The company is expanding capacity and sees significant growth potential in inpatient rehabilitation services. Positive trends in managed care volume and strategic initiatives like the Palantir partnership further bolster sentiment. Despite some uncertainties in Medicare Advantage dynamics, the overall outlook remains optimistic, with solid guidance and strategic expansions. The Q&A section reinforces confidence with detailed responses and plans to address challenges. Consequently, a positive stock price movement is expected over the next two weeks.
Encompass Health Corporation (EHC) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call summary and Q&A indicate positive sentiment: strong financial metrics, optimistic guidance, and strategic expansion plans. Despite a decrease in adjusted free cash flow, year-to-date growth is robust. The focus on bed expansion and reduced premium labor costs are favorable. However, management's lack of clarity on certain issues and the absence of a market cap metric slightly temper the outlook. Overall, the strategic initiatives and positive guidance suggest a stock price increase of 2% to 8% over the next two weeks.
Encompass Health Corporation (EHC) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A session indicate positive financial metrics, such as raised guidance for revenue, EBITDA, and EPS for 2025, and strong free cash flow expectations. The company is expanding capacity with new projects and partnerships, and AI is enhancing operations. While there are concerns about management's clarity on certain issues, the overall sentiment is positive, especially with raised guidance and expansion plans. The market strategy and shareholder return plans are also favorable, suggesting a positive stock price movement.
Encompass Health Corporation (NYSE:EHC) Q1 2025 Earnings Call Transcript
Positive4-29
The earnings call indicates strong financial performance with a 10.6% revenue increase and a 14.9% rise in adjusted EBITDA. Share repurchases and dividends further bolster shareholder confidence. The Q&A revealed management's proactive approach to potential risks like benefit expenses and supply costs, without significant concerns. Despite some uncertainties in future costs and trends, the optimistic guidance and strategic expansion plans, such as increased partnerships, suggest a positive outlook for stock price movement.
EHC Slides
EHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
